Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Dr. Nate Zwald, Ph.D., is an Independent Director of CH4 Natural Solutions Corporation (NYSE: MTNE), a special purpose acquisition company that raised approximately $200–250 million in its initial public offering. He joined the board alongside fellow directors Jean Rogers and Ben Veres, with the SPAC led by CEO and Chairman David Leuschen, CFO Thomas Smith, and Prospective Chairman Robert (Bert) Glover. The SPAC, formally known as CH4 Natural Solutions Acquisition Corporation, is focused on identifying a business combination in the natural solutions and agriculture space. Zwald's appointment as a director was disclosed in the company's S-1 registration statement filed with the SEC, and he has served on the board since the offering's completion. His mailing address on SEC filings is listed as Beaver Dam, Wisconsin 53916, reflecting his deep roots in America's dairy heartland.
Zwald's primary career has been built over more than 20 years in the cattle genetics and dairy industries, where he is widely recognized as one of the most experienced leaders in modern dairy genetics. He currently serves as President and Chief Operating Officer of Progenco, a Davis, California-based company that operates at the intersection of the dairy and beef industries, utilizing advanced embryo technology and elite terminal Angus genetics to produce high-performance beef animals sustainably. At Progenco, Zwald oversees genetic selection strategies and commercial programs designed to make "better animals faster," leveraging genomic technology, sexed semen, and beef-on-dairy breeding programs. He has been with Progenco since at least March 2025, having previously been identified in some sources as both president and CEO of the company. Prior to Progenco, Zwald served as Chief Operating Officer of ABS Global, Inc., the world leader in bovine genetics, reproduction services, technologies, which he joined in February 2017. He was also formerly CEO of ABS Global, as referenced in podcast appearances. Before his tenure at ABS Global, he held the position of USA General Manager at Alta Genetics, another major player in the animal genetics industry. His work has influenced dairy farming practices across more than 25 countries.
Educationally, Zwald attended the University of Wisconsin-Madison, one of the premier agricultural and dairy science institutions in the United States, and he holds a Ph.D. His career began with hands-on experience growing up on a dairy farm, where he learned about genetics from his father in the barn—an origin story he frequently cites in public appearances and podcasts. He has been a featured guest on industry podcasts such as "The Milk Check" by T.C. Jacoby & Co., where he discussed the accelerating pace of genetic progress, the rise of gender-selected genetics, the decline of dairy bull calves, and the potential of embryo technology as the next major leap in dairy performance. He has also been profiled in industry publications and was the subject of a feature by ABS Global when he joined that company as Dairy COO.
In his SPAC role at CH4 Natural Solutions Corporation, Zwald brings deep domain expertise in agriculture, genetics, and sustainable food production to a board that is seeking a business combination in the natural solutions sector. The SPAC's leadership team combines financial and deal-making experience—Leuschen is a well-known energy and infrastructure investor—with industry specialists like Zwald who understand the operational and scientific dimensions of agriculture and natural systems. As an independent director with a tenure of less than a year as of mid-2026, Zwald's track record of building people-centric cultures focused on commercial excellence, combined with his two decades of leadership across three major genetics companies, positions him as a valuable strategic voice on the MTNE board as it pursues its initial business combination.
This record is keyed to SEC CIK 0002053740 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 6 institutional-holder rows on these vehicles, under 6 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.